Organon & Co. - OGN STOCK NEWS

Organon reported 2021 revenue of $6.3 billion, a 3% decline from 2020, driven by losses in Established Brands. However, Nexplanon and biosimilars saw double-digit growth. Q4 revenue decreased by 1%, with a significant 46% drop in net income from continuing operations year-on-year. The company anticipates 2022 revenue between $6.1 billion and $6.4 billion, with adjusted EBITDA margins projected at 34%-36%. A quarterly dividend of $0.28 was declared, payable on March 17, 2022.

Organon (NYSE: OGN) has announced the acquisition of rights to Marvelon® and Mercilon® contraceptive pills from Bayer AG in China, Hong Kong, and Macau, with an additional agreement for Vietnam expected to close in H1 2022 pending regulatory approval. This acquisition expands Organon's contraceptive portfolio, providing opportunities to reach more women in these markets. Currently, Marvelon and Mercilon are available over the counter in China and Hong Kong, while they are prescription-based in Vietnam. This strategic move aligns with Organon’s goal to enhance women’s health offerings globally.

Organon (NYSE: OGN), a global women's health company, is designating International Women’s Day on March 8 as a day for employees to focus on their health. The initiative highlights growing health disparities faced by women, worsened by the COVID-19 pandemic. Organon is urging employers in the UK to provide similar support. Acknowledging that 78% of women neglect their health for others, the company encourages its almost 9,500 employees to utilize this time off to prioritize their well-being, a step towards raising awareness on women's health inequities.

Organon (NYSE: OGN) highlights the disparities in women’s health exacerbated by the COVID-19 pandemic, urging global leaders to prioritize women’s health. On March 8, International Women’s Day, Organon will give its employees paid time off to focus on their health. The firm stresses that women often neglect their health needs, with 78% prioritizing family over personal healthcare. CEO Kevin Ali emphasizes the importance of women's health for a resilient society. Organon aims to improve awareness and invites others to join in supporting women's health initiatives.

Organon (NYSE: OGN) will announce its fourth quarter and full year 2021 financial results on February 17, 2022, prior to a conference call at 8:30 a.m. EST. Investors can access the live call via webcast on the Organon website, with a replay available shortly after. Institutional investors must register in advance using conference ID# 2682555 to participate. Organon, a spin-off from Merck (NYSE: MRK), focuses on women's health, offering over 60 products and aiming to collaborate with biopharmaceutical innovators in growing markets.

Organon (NYSE: OGN) and Samsung Bioepis announced that the FDA has accepted the supplemental Biologics License Application (sBLA) for SB5, a citrate-free, high-concentration formulation of adalimumab, referencing HUMIRA®. The sBLA, submitted in October 2021, is based on clinical data comparing SB5's pharmacokinetics, safety, and immunogenicity between 100 mg/mL and 50 mg/mL formulations. SB5 is expected to launch in the U.S. on or after July 1, 2023, under a licensing agreement with AbbVie.

Organon (NYSE: OGN) announced that CEO Kevin Ali and CFO Matthew Walsh will engage in a fireside chat at the 40th Annual J.P. Morgan Healthcare Virtual Conference on January 10, 2022, at 2:15 p.m. ET. The event will be accessible via a live audio webcast for investors, analysts, media, and the public. As a global healthcare company focusing on women's health, Organon offers over 60 products and aims to expand its biosimilars business while collaborating with biopharmaceutical innovators. For more details, visit here.

Organon (NYSE: OGN) has completed its acquisition of Forendo Pharma, enhancing its women's health pipeline with novel treatments for endometriosis and polycystic ovarian syndrome (PCOS). The transaction includes a $75 million upfront payment and potential total consideration of up to $954 million based on development and commercial milestones. Forendo's lead candidate, FOR-6219, is entering Phase 2 clinical trials and aims to offer a long-term treatment option for endometriosis, addressing significant unmet needs in women's health.

Organon (NYSE: OGN) announced that CEO Kevin Ali and CFO Matthew Walsh will participate in a fireside chat at the Evercore ISI 4th Annual HealthCONx Conference on December 1, 2021, at 1:50 p.m. ET. Investors, analysts, and the public can access a live video webcast at this link. Organon focuses on women's health and has over 60 products across various therapeutic areas, serving over 140 markets globally and employing approximately 9,000 people.